Key takeaway: The investor presentation from Godavari Biorefineries Limited for the quarter ended June 30, 2026, reported the commencement of operations at its 200 KLPD dual-feedstock distillery in Sameerwadi, Karnataka, which adds 60 million litres of annual ethanol capacity, bringing the total to 800 KLPD. The presentation highlighted a 4.9% year-over-year increase in total income to ₹559.9 crore and a 53% growth in EBITDA for the bio-based chemicals segment. Management noted the successful commissioning of the distillery and improved sugar realizations, while also addressing potential risks related to El Niño. The company emphasized its commitment to sustainability and innovation, with ongoing developments in drug discovery, including a Japanese patent for a novel anti-cancer molecule. The presentation concluded with a focus on expanding capacity and enhancing supply chain resilience.

Key takeaway: The investor presentation from Godavari Biorefineries Limited for the quarter and year ended March 31, 2026, reported a total income of ₹2,000.2 crores, reflecting a 6.0% year-on-year growth. EBITDA increased by 15.8% to ₹139.3 crores, with margins stabilizing at 7.0%. The presentation highlighted a strategic focus on specialty chemicals, with a revenue increase of 12.6% in this segment. GBL's ethanol production reached 98 million liters, with a significant contribution from specialty chemicals. The company emphasized its competitive edge in bio-based solutions amid global energy disruptions and geopolitical volatility. Additionally, GBL's new grain-based distillery is set to enhance ethanol capacity by 60 million liters. The presentation also noted achievements in sustainability and innovation, including awards for operational excellence and advancements in drug discovery.

Key takeaway: In the earnings conference call held on February 19, 2026, management reported a strong improvement in profitability for Q3 FY26, with EBITDA growing approximately 14% year-on-year and profit before tax before exceptional items increasing by about 152%. The decline in finance costs by 48% year-on-year was attributed to improved cash flows and balance sheet strength. The bio-based chemical segment was highlighted as a key contributor to profitability, with EBITDA margins improving significantly. Management noted some softness in the ethanol segment and discussed strategic initiatives, including a US patent grant for a novel anti-cancer molecule and advancements in their DME to CO2 technology. The consumer business, particularly the Jivana brand, showed promising growth, crossing INR100 crores in revenue during the first nine months of FY26. Management emphasized a focus on disciplined execution and capital efficiency moving forward.